Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jango-HPO-C1
- Development stage
- Preclinical
- Lead developer
- JangoBio
- Modality
- Cell Therapies
- Administration
- Implant
01
Overview
Jango-HPO-C1 is a canine-specific cell therapy candidate developed by JangoBio, utilizing their proprietary Hormone-Producing Organoid (HPO) technology. The therapy involves the implantation of bioengineered organoids designed to restore a natural, physiological balance of hormones, addressing the multi-hormonal decline associated with aging and hypogonadism. Unlike traditional single-hormone replacement therapies, Jango-HPO-C1 aims to provide a sustainable and comprehensive endocrine solution. It is currently in preclinical development (Proof of Concept stage) for the treatment of hypogonadism and the promotion of healthy aging in dogs.
- Other names
- canine HPOcanine Hormone-Producing Organoid
Beyond the preview
Go deeper on Jango-HPO-C1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jango-HPO-C1.